 |
|
Macular Grid Photocoagulation After Intravitreal Triamcinolone Acetonide for Diffuse Diabetic Macular Edema
Se Woong Kang, MD;
Ho-Seok Sa, MD;
Hee Yoon Cho, MD;
Jong In Kim, MD
Arch Ophthalmol. 2006;124:653-658.
Objective To evaluate the clinical outcomes of macular laser photocoagulation after the intravitreal injection of 4 mg of triamcinolone acetonide (IVTA) for diffuse diabetic macular edema (DME).
Methods Eighty-six eyes of 74 patients with diffuse DME were randomized into 2 groups. The laser group eyes (n = 48) were subjected to a macular grid laser photocoagulation 3 weeks after IVTA. The control group eyes (n = 38) underwent only IVTA. Both groups were compared with regard to the changes in visual acuity and central macular thickness at 3 weeks, 3 months, and 6 months after IVTA.
Results The mean central macular thickness before, 3 weeks after, and 3 and 6 months after IVTA were 538, 250, 295, and 301 µm in the laser group vs 510, 227, 302, and 437 µm in the control group, respectively. The logMAR visual acuities were not significantly different between the 2 groups at baseline and at 3 weeks after IVTA but were significantly better in the laser group at 3 (P = .02) and 6 months (P<.001) after IVTA.
Conclusions Macular laser coagulation effectively maintains improved visual acuity after IVTA for diffuse DME and is believed to reduce recurrent DME after IVTA.
Author Affiliations: Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Management of Diabetic Retinopathy: A Systematic Review
Mohamed et al.
JAMA 2007;298:902-916.
ABSTRACT
| FULL TEXT
Combined triamcinolone acetonide injection and grid laser photocoagulation: a promising treatment for diffuse diabetic macular oedema?
Iida
Br. J. Ophthalmol. 2007;91:407-408.
FULL TEXT
Intravitreal triamcinolone for diffuse diabetic macular oedema.
Longo
Br. J. Ophthalmol. 2006;90:1079-1080.
FULL TEXT
|
